# SELLAS REGAL Trial Reaches 80th Death Event, Triggering Final Analysis

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/43000
Published: 2026-10-28T22:04:42.000Z
Updated: 2026-10-28T22:04:42.000Z
Section: Business

> Topline primary-endpoint results from the Phase 3 trial are expected this quarter.

SELLAS Life Sciences Group, Inc. said Oct. 28 that its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached its prespecified 80th death event, triggering a final analysis.

Topline results for the trial’s primary endpoint are expected this quarter.